Compare Citius Pharmaceuticals Inc (CTXR) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Wendys Co — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Wendys Co trades at $6.24 (market cap $1.19B). The key difference: Wendys Co is far larger — about 87.4× Citius Pharmaceuticals Inc's market cap, and Wendys Co pays a 4.49% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Wendys Co for 77 Days on average.
| CTXR | WEN | |
|---|---|---|
Market Cap | $13.62M | $1.19B |
Volume | 132,438 | 5,622,905 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $9.33 |
52-Week Low | $0.48 | $6.10 |
Typical Hold Time | 17 Days | 77 Days |
Enterprise Value | $3.79M | $4.92B |
Dividend Yield | — | 4.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Wendy's stock trades at $6.23, up 1.96% today, but remains under significant pressure with a bearish technical outlook. The company faces declining same-store sales, a major franchisee bankruptcy, and net income margin compression from 7.58% in 2025 to 5.72% projected for 2026. Despite beating earnings expectations in recent quarters, valuation metrics appear attractive with P/E of 9.45 and P/S of 0.54, though high debt levels and competitive pressures persist.
The investment case hinges on new CEO Bob Wright's turnaround execution against substantial headwinds. While the stock trades at a discount to analyst consensus target of $7.58, near-term risks from franchisee instability and market share losses to burger chain competitors outweigh valuation appeal. Recovery depends on reversing sales trends and managing $2.66 billion in long-term debt effectively.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
